Earnings summaries and quarterly performance for Esperion Therapeutics.
Executive leadership at Esperion Therapeutics.
Board of directors at Esperion Therapeutics.
Research analysts who have asked questions during Esperion Therapeutics earnings calls.
Joseph Pantginis
H.C. Wainwright & Co.
3 questions for ESPR
Also covers: ARMP, BCDA, BLRX +15 more
SB
Serge Belanger
Needham & Company
3 questions for ESPR
Also covers: AMPH, ARQT, BCRX +12 more
Jason Zemansky
Bank of America
2 questions for ESPR
Also covers: ABOS, BBIO, CYTK +5 more
JF
Jessica Fye
JPMorgan Chase & Co.
2 questions for ESPR
Also covers: ALKS, ALNY, AMRN +23 more
Kristen Kluska
Cantor Fitzgerald
2 questions for ESPR
Also covers: ABEO, ADMA, AQST +24 more
Tom Shrader
BTIG
2 questions for ESPR
Also covers: ABOS, ALDX, ALEC +4 more
Georgia Bank
Jefferies
1 question for ESPR
PC
Paul Choi
Goldman Sachs
1 question for ESPR
Also covers: AMRN, ARVN, ASND +12 more
Recent press releases and 8-K filings for ESPR.
Esperion Outlines Vision 2040, Reports Preliminary 2025 Financials, and Provides 2026 Guidance
ESPR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Esperion reported preliminary U.S. net sales of $156 million-$160 million and total revenue of $400 million-$408 million for the past year, with retail prescriptions growing 34% year over year. The company holds $168 million in preliminary cash and aims for sustainable profitability in 2026.
- The company's "Vision 2040" aims for at least five marketed products by that year, driven by pipeline advancements including a triple combination product expected to launch in H2 2027 and ESP-2001 for primary sclerosing cholangitis, with clinical trials anticipated before the end of 2026.
- Esperion is expanding globally, with a recent launch in Japan and planned launches in Canada, Israel, Australia, and New Zealand by the end of 2026. Market exclusivity for bempedoic acid products is secured with some generic filers until 2040.
- Operating expense guidance for 2026 includes R&D of $40-$50 million and SG&A of $170-$195 million, for a total OPEX of $210-$245 million.
Jan 14, 2026, 10:15 PM
Esperion Reports Strong Preliminary 2025 Results and Outlines 2026 Growth Catalysts
ESPR
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Esperion reported strong preliminary 2025 financial results, with U.S. net product sales of $156M - $160M and total preliminary revenue of $400M - $408M, reflecting significant year-over-year growth.
- The company achieved a strong financial position in 2025, ending the year with $168M in cash and cash equivalents and repaying $55M of debt, with a target to reach sustainable profitability in 2026.
- Commercial execution in 2025 was robust, marked by a +34% increase in Retail Prescription Equivalents and a ~25% expansion in its prescriber base.
- Esperion anticipates several growth catalysts for 2026 and beyond, including expected inclusion in U.S. guidelines, potential market exclusivity expansion, and continued commercial investment.
- The pipeline advanced with the progression of a triple combination program, with approval anticipated in 2027, and the selection of ESP-2001 as a lead preclinical candidate.
Jan 14, 2026, 10:15 PM
Esperion Pre-Announces Strong 2025 Results and Outlines Vision 2040
ESPR
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Esperion pre-announced strong preliminary 2025 financial results, including U.S. net sales of $156 million-$160 million and total revenue of $400 million-$408 million, with preliminary cash at $168 million.
- The company aims to achieve sustainable profitability in 2026 and provided full-year 2026 operating expense guidance of $210 million-$245 million.
- Esperion is focused on strengthening its bempedoic acid franchise, which it believes represents a billion-dollar opportunity in the United States, and is expanding globally with recent launches in Japan and planned launches in Canada, Australia, New Zealand, and Israel by the end of 2026.
- The company plans to launch an oral triple combination product in the second half of 2027 and advance its pipeline, including ESP-2001 for primary sclerosing cholangitis, with a goal of having at least five marketed products by 2040.
- A tech transfer for manufacturing to Daiichi Sankyo is underway, with approval for Nilemdo already granted and Nexlizet expected by year-end, which is anticipated to lead to a vast improvement in gross margins.
Jan 14, 2026, 10:15 PM
Esperion Provides 2025 Preliminary Results and 2026 Outlook at J.P. Morgan Conference
ESPR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Esperion anticipates achieving sustainable profitability in 2026. The company reported preliminary 2025 U.S. net sales of $156 million to $160 million and total revenue of $400 million to $408 million, with total revenue (excluding milestones) growing 60% year over year.
- The company's lead products, NEXLETOL and NEXLIZET, saw 34% year-over-year growth in retail prescription equivalents in 2025, with market exclusivity secured until 2040 for several generic filers. New U.S. guidelines from ACC/AHA are expected by the end of February 2026, which could further expand the market.
- Esperion plans to launch an oral triple combination therapy in the second half of 2027 and expects to enter the clinic with ESP-2001 for primary sclerosing cholangitis before the end of 2026.
- Full-year 2026 operating expense guidance is projected between $210 million and $245 million. The company is also pursuing financially affordable, non-dilutive, and immediately accretive acquisitions to expand its portfolio to five marketed products by 2040.
Jan 14, 2026, 10:15 PM
Esperion Therapeutics Provides Preliminary Full-Year 2025 Results and 2026 Guidance
ESPR
Earnings
Guidance Update
New Projects/Investments
- Esperion reported preliminary full-year 2025 U.S. net product sales of $156 to $160 million, representing a 35% to 38% increase over full-year 2024, and preliminary total revenue of $400 to $408 million, a 20% to 23% increase compared to full-year 2024.
- The company ended 2025 with approximately $168 million in cash and cash equivalents.
- For full-year 2026, Esperion expects operating expenses to range between $210 million and $245 million, with research & development expenses projected at $40 million to $50 million and selling, general and administrative expenses at $170 million to $195 million.
- Esperion introduced its Vision 2040 Growth Strategy aimed at transforming into a multi-product global pharmaceutical company, expanding its cardiometabolic franchise, and diversifying into rare hepatic and renal diseases.
- Global expansion highlights include a $90 million payment from Otsuka Pharmaceutical Co. Ltd. for regulatory approval in Japan and the nomination of ESP-2001 for Primary Sclerosing Cholangitis, a wholly owned asset with a potential $1 billion annual market opportunity.
Jan 12, 2026, 1:00 PM
Esperion Reports Preliminary 2025 Financial Results and Introduces Vision 2040
ESPR
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Esperion reported preliminary full-year 2025 U.S. net product sales of $156 to $160 million, representing a 35% to 38% increase compared to 2024, and total preliminary revenue of $400 to $408 million, a 20% to 23% increase.
- The company ended 2025 with approximately $168 million in cash and cash equivalents and provided full-year 2026 operating expense guidance of $210 million to $245 million.
- Esperion introduced its Vision 2040 growth strategy and secured settlement agreements with ANDA filers, restricting generic entry for certain patents until April 2040 or June 2040.
- Significant commercial progress in 2025 included expanded access and reimbursement for NEXLETOL and NEXLIZET, a 24% increase in prescribing healthcare providers, and a $90 million payment from its Japan partner.
- The R&D pipeline advanced with the nomination of ESP-2001 for primary sclerosing cholangitis, a wholly-owned asset with a potential market opportunity exceeding $1 billion annually, with an IND submission targeted for 2026.
Jan 11, 2026, 11:00 PM
Esperion's Bempedoic Acid Receives Recommendation in ACC Scientific Statement
ESPR
- Esperion's bempedoic acid has been included as a first-line, evidence-based therapy for LDL-C lowering in the 2025 American College of Cardiology (ACC) Scientific Statement on Management of Peripheral Artery Disease (PAD) in Adults with Diabetes.
- The ACC statement emphasizes bempedoic acid's role in reducing both cardiovascular and limb risk in high-risk populations, recommending its use to achieve LDL-C target reductions of >50% and a goal of <55 mg/dL.
- Data from the CLEAR Outcomes trial, incorporated into the scientific statement, demonstrated that bempedoic acid reduced major adverse limb events (MALE) by 36% compared to placebo in patients with pre-existing PAD.
- Esperion anticipates that bempedoic acid will be included in the forthcoming U.S. dyslipidemia treatment guidelines from ACC/American Heart Association (AHA) in early 2026, consistent with its endorsement in European guidelines.
Dec 19, 2025, 1:00 PM
Esperion Therapeutics Highlights Bempedoic Acid's Market Expansion, Strong Performance, and Pipeline Progress
ESPR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Bempedoic acid (Nexletol/Nexlizet) has achieved strong access, volume, and sales growth, with a broad label expansion in April 2024 increasing its Total Addressable Market (TAM) from 10 million to 70 million patients.
- The drug received a Class 1A recommendation in European guidelines, positioning it as a foundational lipid-lowering therapy, with similar U.S. guidelines anticipated in early 2025.
- Esperion has secured patent exclusivity for bempedoic acid until at least 2031, with confidence in extending it "well into the 2030s".
- International markets are performing strongly, with Europe having over 600,000 patients on the drug and Japan's recent approval triggering a $90 million milestone payment.
- The company is developing a triple combo pill for market entry by end of 2027 and advancing a next-generation ACLY inhibitor (ESP-2001) into human studies by late 2026.
Dec 3, 2025, 8:30 PM
Esperion Therapeutics Discusses Bempedoic Acid Market Expansion, Guidelines, and Exclusivity
ESPR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Esperion Therapeutics highlighted the broad label expansion for bempedoic acid in April 2024, which increased its Total Addressable Market (TAM) from 10 million to 70 million patients, enabling promotion for use with or without statins.
- Bempedoic acid received a Class I-A recommendation in the European Society of Cardiology (ESC) guidelines for statin-intolerant patients, positioning it as a foundational therapy, with similar positive influence anticipated for upcoming U.S. guidelines.
- The company maintains strong payer access in the U.S., with 90% commercial coverage and 85% Medicare coverage. Internationally, Europe has over 600,000 patients with high double-digit growth, and a $90 million milestone was received for the recent approval in Japan.
- Esperion is confident in bempedoic acid's exclusivity until at least 2031, with expectations to extend "well into the 2030s". A triple combo pill is targeted for market by the end of 2027, and a next-generation ACLY inhibitor (ESP-2001) is expected to be IND-enabled by late 2026.
Dec 3, 2025, 8:30 PM
Esperion Therapeutics Highlights Bempedoic Acid Market Expansion and Future Outlook
ESPR
Product Launch
Legal Proceedings
New Projects/Investments
- Esperion's bempedoic acid saw its Total Addressable Market (TAM) expand from 10 million to 70 million patients in April 2024 following a broad label expansion.
- The drug received a Class 1A recommendation in the European Society of Cardiology (ESC) guidelines, positioning it as foundational therapy, with similar U.S. guidelines anticipated in early 2026.
- U.S. payer access is strong, with 90% commercial coverage and 85% Medicare coverage, and the company expects to be selling exclusively "well into the 2030s" due to patent settlements.
- International markets are performing well, with over 600,000 patients on the drug in Europe and a $90 million milestone received for the Japan launch.
- Esperion is developing a triple combination pill with bempedoic acid and ezetimibe, aiming for market entry by the end of 2027, and advancing a next-generation ACLY inhibitor (ESP-2001) into human studies by late 2026.
Dec 3, 2025, 8:30 PM
Quarterly earnings call transcripts for Esperion Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more